- Home
- IMUX vs LNZA Comparison
IMUX vs LNZA Comparison
Compare IMUX & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- LNZA
- Stock Information
- Founded
- IMUX 2016
- LNZA 2005
- Country
- IMUX United States
- LNZA United States
- Employees
- IMUX N/A
- LNZA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- LNZA Major Chemicals
- Sector
- IMUX Health Care
- LNZA Industrials
- Exchange
- IMUX Nasdaq
- LNZA Nasdaq
- Market Cap
- IMUX 67.8M
- LNZA 65.7M
- IPO Year
- IMUX N/A
- LNZA N/A
- Fundamental
- Price
- IMUX $0.96
- LNZA $0.42
- Analyst Decision
- IMUX Strong Buy
- LNZA Hold
- Analyst Count
- IMUX 5
- LNZA 2
- Target Price
- IMUX $7.50
- LNZA $2.00
- AVG Volume (30 Days)
- IMUX 1.1M
- LNZA 2.6M
- Earning Date
- IMUX 08-11-2025
- LNZA 08-07-2025
- Dividend Yield
- IMUX N/A
- LNZA N/A
- EPS Growth
- IMUX N/A
- LNZA N/A
- EPS
- IMUX N/A
- LNZA N/A
- Revenue
- IMUX N/A
- LNZA $48,831,000.00
- Revenue This Year
- IMUX N/A
- LNZA $58.17
- Revenue Next Year
- IMUX N/A
- LNZA $10.92
- P/E Ratio
- IMUX N/A
- LNZA N/A
- Revenue Growth
- IMUX N/A
- LNZA N/A
- 52 Week Low
- IMUX $0.56
- LNZA $0.14
- 52 Week High
- IMUX $2.11
- LNZA $2.74
- Technical
- Relative Strength Index (RSI)
- IMUX 55.60
- LNZA 57.06
- Support Level
- IMUX $0.94
- LNZA $0.29
- Resistance Level
- IMUX $1.18
- LNZA $0.71
- Average True Range (ATR)
- IMUX 0.08
- LNZA 0.08
- MACD
- IMUX 0.01
- LNZA 0.01
- Stochastic Oscillator
- IMUX 40.95
- LNZA 35.16
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.